Breye Therapeutics

All Fund articles Fund PR Portfolio articles Portfolio PR

Strong clinical data for Breye Therapeutics’ lead oral asset danegaptide presented at Angiogenesis, Exudation and Degeneration 2026 symposium

2026.02.092026.02.09 / Prof. Carl D. Regillo, MD, presented clinical data from the Phase 1b trial evaluating Breye Therapeutics’ lead candidate, danegaptide, in 24 patients with non-proliferative diabetic retinopathy (NPD ...

Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic Retinopathy

2024.01.252025.12.01 / • Investigating potential for an oral treatment in diabetic retinopathy• First patient dosed in Phase 1b/2a clinical trial Copenhagen, Denmark, 25 January 2024 – Breye Therapeutics ApS (Breye), a ...

The oral therapeutic that could change our approach to retinal disease. An inflammation-based view of both ophthalmic and neurologic health

2023.11.032025.12.02 / Dr Burian said oral therapies can also function in conjunction with therapies currently on the market. In late July, biotech incubator Golgi Neurosciences S.r.l. and biopharmaceutical company Bre ...

Golgi Neurosciences and Breye Therapeutics announce successful closing of P2X7 receptor antagonist program transfer

2023.08.082025.06.25 / 25 July 2023 Collaboration to advance development of innovative oral small molecule therapeutics for retinal disorders Milan, Italy and Copenhagen, Denmark, 25 July 2023 – Golgi Neuroscien ...

Breye Therapeutics Strengthens Management Team and Board

2023.04.202025.06.25 / Industry veteran Dr. Peter Adamson, PhD appointed as Chief Scientific Officer Dr. Gabriela Burian, MD appointed to the Board of Directors Copenhagen, Denmark, 20 April 2023 – Breye Therapeuti ...

Brey Therapeutics

A visionary journey to innovate sight-preserving therapies

2023.01.252024.05.13 / Breye Therapeutics is all about the people. Whether it’s the company’s team or the patients whose eyesight they seek to protect, the focus is consistently on the human factor. It’s a value influenced ...

Brey Therapeutics

Novo Holdings and Sound Bioventures launch Breye Therapeutics to develop novel oral therapies for ophthalmologic diseases

2022.11.102024.05.13 / Industry expert Ulrik Mouritzen M.D. appointed Chief Executive OfficerFunding to advance lead asset to phase 1b clinical trial and further build pipeline Copenhagen, Denmark, 10 November 2022 – Br ...